Image-Guided Surgical Device Failures in Functional Endoscopic Sinus Surgery: A MAUDE Analysis

Objective Image-guided surgery (IGS) devices have become widely used for anatomic localization during functional endoscopic sinus surgery (FESS). However, there are no studies that analyze the post-market complications associated with IGS device use during FESS. The objective of this study was to better characterize post-market complications associated with the use of IGS devices during sinus surgery. Methods The US Food and Drug Administration's Manufacturer and User Facility Device Experience database was queried for event reports associated with neurological stereotaxic devices utilized in IGS between the dates of January 1, 2016 and December 31, 2020. Medical device reports that were analyzed for this study pertained strictly to FESS. Results There were 1873 reports involving IGS devices for FESS included in this study. Fifty-five reports involved adverse events to patients (2.9%) and 1818 (97.1%) involved device malfunctions. Of the adverse events to patients, the most common included cerebrospinal fluid leakage (45.6%), tissue damage (12.7%), and nervous system injury (3.6%). The most commonly reported device malfunction was imprecision (21.1%). Conclusion IGS devices are widely utilized in FESS. Of the medical device reports between 2016 and 2020, less than 3% resulted in adverse events. Further studies of the infrequent post-market complications of IGS devices used in FESS can help guide surgeons on the risks of their clinical use. Level of Evidence 4-Retrospective database survey without controls Laryngoscope, 2022

Automated summary

Objective image-guided surgery (IGS) devices are widely used in functional endoscopic sinus surgery (FESS), but there are no studies analyzing post-market complications. This study aimed to characterize post-market complications associated with the use of IGS devices during sinus surgery. The analysis of US FDA's database revealed that less than 3% of medical device reports between 2016 and 2020 resulted in adverse events.